Printer Friendly

PHARMACEUTICAL INDUSTRY DEVELOPS 263 MEDICINES FOR USE IN WOMEN

 PHARMACEUTICAL INDUSTRY DEVELOPS 263 MEDICINES FOR USE IN WOMEN
 ST. PAUL, Minn., Feb. 19 /PRNewswire/ -- A new Pharmaceutical Manufacturers Association (PMA) survey has found that 263 medicines are in human clinical trials or awaiting approval at the Food and Drug Administration for diseases that exclusively or disproportionately affect women or are the top 10 causes of death in women.
 "With 79 companies involved in these research projects, virtually every major pharmaceutical company is addressing the need to develop medicines in a way that takes into account the special medical needs of women," said Paula Johnson, senior regional director of the PMA, at a seminar held today on women's health issues.
 Essential metabolic differences between men and women can create important differences in their ability to metabolize, absorb and transport drugs to key areas of the body. The possibility of pregnancy and damage to the fetus are other important considerations when testing drugs in women.
 Several diseases were found to disproportionately affect women in Minnesota:
 -- Heart disease, cancer and cerebrovascular disease were the
 leading causes of death in women in Minnesota in 1989.
 -- 3,200 women in 1991 in Minnesota were diagnosed with breast
 cancer.
 -- 65 percent of deaths in Minnesota from heart disease occurred
 in women.
 -- 61 percent of all deaths in Minnesota from strokes occurred in
 women.
 Key findings in the survey report, called "New Medicines in Development for Women," include:
 -- In testing for breast cancer, the number two cause of cancer
 death in women, are 37 medicines -- more than for any other
 disease of women.
 -- The top three major categories of research are cardiovascular/
 cerebrovascular disease with 48 medicines in development,
 cancer with 58, and obstetric and gynecologic diseases with
 51.
 -- The top three causes of death among women -- heart disease,
 cancer and cerebrovascular disease -- are the focus of 40
 percent of the research.
 -- The number one cause of cancer deaths in women -- lung cancer
 -- has 29 medicines in development.
 -- Ovarian cancer, which will strike one out of every 70 women
 during her lifetime, has 31 medicines in development.
 -- Another 37 medicines are in testing for five specific types of
 arthritis and other musculoskeletal diseases. As many as 90
 percent of the people who suffer from these diseases are
 women.
 -- The 263 medicines involve 355 research projects, because some
 of the drugs are being tested for more than one use.
 -- More than 50 percent of the research projects are in their
 final stages of development.
 The report includes a list of the medicines in development, the companies developing the medicines, the diseases for which each drug is being tested and each drug's development status. Each medicine listed is either being tested to see if it should be developed for use in women or specifically includes women in clinical trials.
 The Pharmaceutical Manufacturers Association is a non-profit scientific and professional organization of more than 100 member companies that discover, develop and produce most of the prescription drugs used in the United States.
 NOTE: Copies of the survey report are available free of charge by writing: Editor, "New Medicines in Development for Women," Pharmaceutical Manufacturers Association, 1100 15th St., N.W., Washington, D.C. 20005.
 -0- 2/19/92
 /CONTACT: Mark E. Grayson of the Pharmaceutical Manufactueres Association, 612-228-1929/ CO: Pharmaceutical Manufactueres Association ST: Minnesota IN: HEA SU:


MK-SB -- DC008 -- 0349 02/19/92 10:37 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 19, 1992
Words:557
Previous Article:CON ED $1.7 BILLION 'AA' FIRST & REFUNDING MORTGAGE BONDS AFFIRMED BY FITCH -- FITCH FINANCIAL WIRE --
Next Article:CONSUMER PRICES JUMPED 0.6 PERCENT IN JANUARY IN THE WEST REGION, UP 2.8 PERCENT FOR THE YEAR
Topics:


Related Articles
INDUSTRY IS DEVELOPING 263 MEDICINES FOR USE IN WOMEN
Medicines to Treat Women's Health A Key Priority for Roche.
Three Large Clinical Studies Demonstrate Arava(TM) (Leflunomide) Maintains Improved Signs and Symptoms of Rheumatoid Arthritis Over Time.
Health and Pharmaceuticals.
83 New Medicines in Development for HIV/AIDS.
Healthcare Businesswomen's Association Names Christine Poon, Johnson & Johnson, 2004 Woman Of The Year.
BioSante Pharmaceuticals Licenses Hormone Therapy Technology From Wake Forest University.
Dr. David Karlin Joins Cellegy Pharmaceuticals as Vice President, Clinical Research.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters